Ingenol Mebutate

CHEMBL1863513 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
430.5 g/mol
LogP
2.0
Phase
4

This topical gel is derived from the Euphorbia peplus plant and is used to treat actinic keratoses, precancerous skin lesions caused by sun damage. It works through two mechanisms: direct necrosis of abnormal skin cells and stimulation of a local immune response that clears residual abnormal cells. Treatment involves applying the gel for only 2-3 consecutive days.

分子量

430.5000 g/mol

LogP

2.00

TPSA

104.00 Ų

Lipinski 五规则

符合

作用机制

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C

InChI

InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1

Molecular Formula

C25H34O6

HBD / HBA

3 / 6

可旋转键数

4

重原子数

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This topical gel is derived from the Euphorbia peplus plant and is used to treat actinic keratoses, precancerous skin lesions caused by sun damage. It works through two mechanisms: direct necrosis of abnormal skin cells and stimulation of a local immune response that clears residual abnormal cells. Treatment involves applying the gel for only 2-3 consecutive days.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Ingenol Mebutate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1863513. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6918670. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.